CSI Market
Sign In | Register

Nrx Pharmaceuticals Inc (NRXP) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access NRXP quarterly Cash Flow →
This page allows investors to follow Nrx Pharmaceuticals Inc's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-28.62
Depreciation & amortization0.07
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.04
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.83
Income (Loss) from Equity Method Investments, Net of Dividends or Distributions0.04
Fair Value Adjustment of Warrants6.20
Marketable Securities Gain Loss-
Gain Loss On Fair Value Of Cash Earnout Liability-
Embedded Derivative Gain Loss On Embedded Derivative Net-
Noncash Settlement Expense-
Non Cash Consulting Expense-
Fair Value Adjustment Of Convertible Debt-
Contract Costs-
Loss On Contract Termination For Default-
Noncash Litigation Expense-
Increase Decrease In Insurance Loan Payable-
Gain Loss On Consideration Shares And Warrants-
Fair Value Adjustment Of Convertible Debt Net3.94
Gain Loss On Convertible Debt Redemption6.20
Operating Lease Right Of Use Asset Amortization Expense-5.37
Debt Issuance Costs0.73
Increase Decrease In Operating Lease Liability-
Increase Decrease In Operating Lease Liability-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.05
Increase (Decrease) in Accounts Payable0.11
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.50
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.87
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.31
Discontinued operations0.00
Net Cash flow from Operating Activities-14.11
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Cash Withdrawn To Pay Franchise Taxes-
Cash Withdrawn From Trust Account To Pay Redeeming Stockholders-
Cash Withdrawn From Trust Account To Pay Franchise Taxes-
Conversion Of Stock Amount Converted-
Debt Conversion Converted Instrument Amount12.79
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments-0.43
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired-2.38
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-12.79
Discontinued operations0.00
Net Cash Flow from Investing Activities-2.81
Financing Activities
Short-term debt Net0.00
Other borrowing transactions2.74
Long-term debt - borrowings5.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock6.39
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Or Sale Of Private Placement Units-
Net Proceeds From Payments For Issuance Of Common Stock And Warrants In Private Placement Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock And Exercise Of Stock Options-
Repayments Of Convertible Note-
Repayments Of Insurance Loan-
Proceeds From Issuance Of Insurance Loan-
Repayments Of Insurance Loans-0.55
Proceeds From Issuance Of Common Stock And Warrants Net9.47
Proceeds From Insurance Loans0.23
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities23.28
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-14.11
Total Cash Flow6.35
4 historic quarters locked

Sign in to unlock the full Nrx Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Nrx Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001437749-26-009418

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document